On October 1, Liquidia Technologies Inc fell 45.41% in regular trading, trading at $38.115 per share, with turnover of approximately $401 million. The sharp decline was triggered by an unfavorable patent litigation ruling that directly undermined market confidence in the company's commercial outlook.

According to publicly available disclosures, a U.S. District Court ruled that two of the six claims asserted against Liquidia in the Hatch-Waxman litigation tied to the '327 patent are valid and infringed. The parties have been directed to submit a form of judgment specifying the proposed remedy. The ruling raises the risk that Liquidia's core product, YUTREPIA (treprostinil) inhalation powder, could face patent infringement damages or restrictions on commercialization, introducing significant uncertainty to its growth trajectory.

Notably, YUTREPIA had been on a strong commercial ramp, generating approximately $170.4 million in net product sales in Q2 with around 5,900 unique patient prescriptions, and Q2 EPS of $0.74 representing a swing from a year-ago loss. The patent ruling now casts doubt on whether this momentum can be sustained.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)